atumelnant — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's
Phase 1/2 · Cushing Syndrome, Cushing Disease |
CRNX Crinetics Pharmaceuticals, I | atumelnant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|